Annual report pursuant to Section 13 and 15(d)

Consolidated Statements of Operations and Comprehensive Loss

v3.23.1
Consolidated Statements of Operations and Comprehensive Loss - USD ($)
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Operating Expenses:    
Research and development $ 2,191,834 $ 1,000,769
Research and development - related parties 240,731 2,947,536
General and administrative 15,459,788 11,230,118
General and administrative - related parties 5,612 462,580
Total Operating Expenses 17,897,965 15,641,003
Loss From Operations (17,897,965) (15,641,003)
Other (Expenses) Income:    
Gain on settlement of liabilities 926,829
Other expense (146,822)
Interest expense (26,667) (186,208)
Loss on extinguishment of convertible notes payable, net (9,737)
Loss on goodwill impairment (33,547,278)
Loss on IP R&D impairment (3,342,084)
Change in fair value of derivative liabilities 15,144,986 (4,677,388)
Change in fair value of accrued issuable equity 9,405
Offering costs allocated to warrant liabilities 604,118
Total Other Expense, Net (21,771,043) (4,706,849)
Loss Before Income Taxes (39,669,008) (20,347,852)
Income tax benefit 942,749 23,204
Net Loss Attributable to Common Stockholders (38,726,259) (20,324,648)
Other Comprehensive (Loss) Income:    
Foreign currency translation adjustments (3,702,963) 180,554
Total Comprehensive Loss $ (42,429,222) $ (20,144,094)
Basic and Diluted Net Loss per Common Share (in Dollars per share) $ (20.38) $ (12.96)
Weighted Average Number of Common Shares Outstanding: (in Shares) 1,900,397 1,567,772